Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant respiratory distress syndrome.
Mar 7, 2012
0
0